A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Trial Profile

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs Xaliproden (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 20 Aug 2008 Official title and primary outcomes amended as reported by ClinicalTrial.gov
    • 20 Aug 2008 Actual patients number (1306) amended as reported by ClinicalTrials.gov
    • 20 Aug 2008 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top